Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Apr 22 03:29PM ET
2.84
Dollar change
+0.01
Percentage change
0.35
%
IndexRUT P/E- EPS (ttm)-1.12 Insider Own4.31% Shs Outstand69.91M Perf Week5.58%
Market Cap199.65M Forward P/E- EPS next Y-0.68 Insider Trans-0.66% Shs Float67.27M Perf Month-18.62%
Income-76.24M PEG- EPS next Q-0.18 Inst Own79.62% Short Float3.54% Perf Quarter1.07%
Sales70.14M P/S2.85 EPS this Y42.35% Inst Trans-3.44% Short Ratio4.05 Perf Half Y68.55%
Book/sh1.24 P/B2.29 EPS next Y-5.83% ROA-39.41% Short Interest2.38M Perf Year-30.73%
Cash/sh0.93 P/C3.04 EPS next 5Y15.00% ROE-65.89% 52W Range1.45 - 4.91 Perf YTD-6.89%
Dividend Est.- P/FCF- EPS past 5Y-39.95% ROI-77.12% 52W High-42.16% Beta2.05
Dividend TTM- Quick Ratio2.53 Sales past 5Y9.69% Gross Margin73.87% 52W Low95.86% ATR (14)0.21
Dividend Ex-Date- Current Ratio2.61 EPS Y/Y TTM-117.91% Oper. Margin-78.13% RSI (14)37.57 Volatility6.74% 5.58%
Employees174 Debt/Eq0.26 Sales Y/Y TTM-49.39% Profit Margin-108.69% Recom1.29 Target Price6.57
Option/ShortYes / Yes LT Debt/Eq0.14 EPS Q/Q46.18% Payout- Rel Volume0.26 Prev Close2.83
Sales Surprise33.46% EPS Surprise19.55% Sales Q/Q-12.56% EarningsMay 02 AMC Avg Volume588.61K Price2.84
SMA20-10.22% SMA50-14.18% SMA20010.22% Trades Volume142,840 Change0.35%
Date Action Analyst Rating Change Price Target Change
Feb-29-24Upgrade The Benchmark Company Hold → Buy
Nov-07-23Downgrade The Benchmark Company Buy → Hold
Aug-07-23Downgrade TD Cowen Outperform → Market Perform $21 → $4
May-09-23Downgrade H.C. Wainwright Buy → Neutral
Mar-31-22Resumed Piper Sandler Overweight $35
Mar-02-22Resumed Cowen Outperform
Apr-12-21Initiated Piper Sandler Overweight $32
Mar-01-21Initiated Stifel Buy $30
Feb-26-21Reiterated H.C. Wainwright Buy $21 → $26
Mar-10-20Initiated The Benchmark Company Buy
Apr-18-24 04:05PM
Apr-11-24 07:05AM
Feb-29-24 10:40AM
07:08AM
Feb-28-24 06:50PM
06:01PM Loading…
06:01PM
04:59PM
04:05PM
Feb-26-24 04:05PM
08:05AM
Feb-20-24 08:05AM
Feb-14-24 04:05PM
Feb-13-24 04:05PM
Feb-01-24 04:05PM
Jan-08-24 07:03PM
08:30AM Loading…
Dec-27-23 08:30AM
Dec-14-23 06:45AM
Dec-13-23 04:06PM
04:05PM
Dec-11-23 07:05AM
Nov-29-23 02:46PM
Nov-28-23 04:05PM
Nov-14-23 04:05PM
Nov-03-23 09:14AM
08:58AM
Nov-02-23 06:24PM
05:04PM
04:05PM
Oct-31-23 04:05PM
Oct-27-23 03:35PM
04:05PM Loading…
Oct-26-23 04:05PM
Oct-19-23 04:05PM
Sep-29-23 07:05AM
Sep-18-23 04:05PM
Sep-16-23 03:02PM
Sep-13-23 01:02AM
Sep-12-23 04:05PM
Sep-11-23 08:21AM
Sep-08-23 04:44PM
Sep-07-23 04:05PM
Aug-24-23 09:29AM
Aug-08-23 06:00PM
Aug-03-23 06:25PM
05:18PM
04:05PM
Jul-31-23 04:05PM
Jul-20-23 05:51PM
04:05PM
Jul-11-23 10:00AM
Jul-10-23 06:09AM
Jul-08-23 08:50PM
Jun-09-23 04:05PM
Jun-08-23 08:18AM
May-24-23 04:05PM
May-10-23 04:05PM
May-08-23 04:05PM
May-04-23 07:05PM
06:02PM
04:05PM
May-01-23 10:01AM
Apr-28-23 07:59AM
Apr-27-23 10:03AM
Apr-20-23 04:05PM
Apr-19-23 04:05PM
Apr-06-23 04:05PM
Apr-04-23 04:05PM
Mar-27-23 07:33AM
Mar-09-23 04:05PM
Feb-27-23 04:05PM
05:14AM
Feb-24-23 10:13AM
Feb-23-23 07:00PM
04:06PM
04:05PM
Feb-22-23 04:05PM
Feb-15-23 04:05PM
Feb-09-23 04:05PM
Feb-07-23 10:07AM
Jan-30-23 05:57AM
Jan-23-23 04:05PM
Dec-20-22 04:05PM
08:15AM
Nov-30-22 08:30AM
Nov-29-22 04:05PM
Nov-16-22 04:05PM
Nov-09-22 06:00AM
Nov-08-22 04:05PM
Nov-07-22 09:55AM
Nov-03-22 05:45PM
04:05PM
Nov-02-22 12:42PM
Nov-01-22 08:00AM
Oct-20-22 04:05PM
Oct-03-22 08:00AM
08:00AM
Sep-14-22 04:05PM
Aug-04-22 06:05PM
04:05PM
Aug-02-22 04:05PM
Aug-01-22 10:01AM
Codexis, Inc. is an enzyme engineering company, which engages in the development and sale of therapeutics. It operates through the Performance Enzymes and Novel Biotherapeutics segments. The Performance Enzymes segment commercializes CodeEvolver protein engineering technology platform and products in the pharmaceuticals market. The Novel Biotherapeutics segment targets new opportunities to discover and improve biotherapeutic drug candidates. Its products include screening kits and Codex HiFi Hot Start DNA Polymerase. The company was founded in January 2002 and is headquartered in Redwood City, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Dorgan Byron LDirectorNov 15 '23Sale2.1120,00042,168193,461Nov 17 05:14 PM
Norrett KevinChief Operating OfficerSep 11 '23Buy1.729,00015,47998,102Sep 12 04:07 PM
DILLY STEPHEN GEORGESee RemarksSep 08 '23Buy1.7358,479100,952438,878Sep 12 04:06 PM
Fitzgerald Margaret NellSee RemarksSep 08 '23Buy1.7011,83420,06581,420Sep 12 04:06 PM
Ryali SriramChief Financial OfficerSep 08 '23Buy1.7011,65019,856123,441Sep 12 04:07 PM